Peer-reviewed veterinary case report
Lipoxygenase-5 levels in normal, inflamed, and cancerous dog bladders
By Finotello, Riccardo et al.·Published in Journal of comparative pathology·2019·Department of Small Animal Clinical Science, United Kingdom·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Lipoxygenase-5 Expression in Canine Urinary Bladder: Normal Urothelium, Cystitis and Transitional Cell Carcinoma.
- Species:
- dog
Plain-English summary
A study found that transitional cell carcinoma (TCC), a common bladder tumor in dogs, showed a high level of a specific enzyme called lipoxygenase-5 (LOX-5) in 95% of cases. In contrast, only 23% of dogs with cystitis (bladder inflammation) and 10% of healthy dogs had this enzyme present. This suggests that LOX-5 could be a marker for TCC in dogs. The researchers believe that using certain anti-inflammatory medications that target both LOX-5 and another enzyme could be a promising treatment for dogs diagnosed with TCC.
People also search for: dog bladder cancer symptoms · transitional cell carcinoma treatment for dogs · cystitis in dogs causes
Abstract
Transitional cell carcinoma (TCC) is the most common canine urinary tract tumour and mimics human invasive TCC. Human TCCs overexpress lipoxygenase (LOX)-5 and the use of target inhibitors has proven effective in inhibiting neoplastic growth. In this study, we investigated the immunohistochemical expression of LOX-5 in normal canine urinary bladder, cystitis and TCC. The comparative expression of LOX-5, cyclo-oxygenase (COX)-1 and COX-2 among the three tissue groups was also examined. Biopsy samples from cases of cystitis and TCC were reviewed from 2012 to 2016; samples of histologically normal bladder were used as controls. Dogs were excluded if they had received glucocorticoids, non-steroidal anti-inflammatory drugs (NSAIDs) and/or chemotherapy prior to tissue collection. LOX-5 was expressed in 95% of TCCs, 23% of cases of cystitis and 10% of controls. LOX-5 and COX-2 immunohistochemistry scores were significantly (P <0.01) higher in TCCs versus cystitis and normal bladders. Results of this study support the rationale for further investigation of the use of NSAIDs with dual anti COX-2 and LOX-5 effect for the treatment of canine TCC.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31375151/